Sanofi’s Sutimlimab Shows Promise In Rare Blood Disorder
First-In-Class Complement Pathway Inhibitor Impresses In Cold Agglutinin Disease
A Phase III rare-disease hit for Sanofi marks the first of a number of orphan drug read-outs expected in the coming year.
You may also be interested in...
The tireless pace of change in hemato-oncology was showcased in Orlando.
The French drug maker is making a big splash into blood disorders with the $11.6bn acquisition of hemophilia specialist Bioverativ. Eloctate and Alprolix are young and growing brands, but the competition in hemophilia is fierce, which means Bioverativ's pipeline will also need to deliver to justify the premium price.
A first look at the clinical data for Novavax’s COVID-19 vaccine suggests it can produce strong antibody responses while being well tolerated.